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Abstract. Gastroesophageal reflux disease (GERD) in systemic 
sclerosis (SSc) can significantly reduce a patient's quality of 
life. GERD in SSc is occasionally resistant to conventional 
anti‑acid treatment. Vonoprazan is an H+/K+‑ATPase blocker 
that is approved in Japan for treatment of GERD. The aim of 
the present study was to evaluate the efficacy of vonoprazan 
in SSc‑related GERD. The frequency scale for symptoms of 
GERD (FSSG) scores were collected before and after vono‑
prazan treatment in 15 SSc patients with GERD. Additionally, 
endoscopic esophagogastroduodenoscopy was performed in 
select patients. Conventional proton pump inhibitors or hista‑
mine‑2 receptor antagonists had been previously administered 
in 93% (14/15) of the patients. Although the baseline esophago‑
gastroduodenoscopy examination did not show severe erosion 
in the majority of patients, the mean total FSSG score before 
vonoprazan treatment was notably high (25.2±10.7) compared 
to a normal score of <8. After vonoprazan treatment, the 
FSSG score decreased to 9.6±7.0. The mean improvement 
rate of the total FSSG, acid reflux and dysmotility scores 
were 60.8±21.2% (P=0.0004), 67.3±24.8% (P<0.0001) and 
55.4±26.0% (P=0.0022), respectively. These results suggest 
that vonoprazan may be a potentially effective treatment for 
GERD in patients with SSc.
Introduction
Systemic sclerosis (SSc) is an autoimmune disease resulting 
in tissue fibrosis, vascular angiopathy and visceral damage (1). 
Microvascular changes in SSc can lead to muscle fibrosis in the 
digestive system (2), which results in esophageal dysmotility in 
65‑95% of patients (3‑9). SSc patients often present with lower 
esophageal sphincter (LES) dysfunction and low or absent 
primary and secondary peristalsis in the distal esophagus (2), 
leading to gastroesophageal acid reflux and reduced gastric 
acid clearance from the esophagus. As a result, gastroesopha‑
geal reflux disease (GERD), a condition characterized by 
erosions seen on endoscopy, and symptoms such as heartburn, 
occur in 45‑80% of patients with SSc (4,9‑12). Furthermore, 
the presence of esophageal symptoms may predict esophageal 
dysmotility in SSc patients (7).
GERD management includes changes to lifestyle and 
administration of proton pump inhibitors (PPIs), H2 receptor 
antagonists (H2RA), or prokinetic agents to improve gastric 
emptying (13). The last option is surgical intervention (such as 
fundoplication or Roux‑en‑Y reconstruction method) (13). PPIs 
are currently the first‑line therapy for patients with GERD, 
including SSc patients. Whilst conventional PPIs have been 
reported to generally work well in GERD patients with SSc (14), 
another study indicated that patients developed esophageal 
symptoms, such as heartburn (77.4%), dysphagia (14.3%), and 
nausea and vomiting (9.8%) after prolonged treatment with the 
conventional PPI, omeprazole (20 or 40 mg/day) (15). Thus, 
it is crucial to develop treatments that can effectively treat 
GERD in all patients with SSc.
Vonoprazan is a first‑in‑class PPI that was approved for use 
by the Ministry of Health, Labour and Welfare of Japan in 
February 2015 (16). Vonoprazan binds to the H+/K+‑ATPase of 
parietal cells in a K+‑competitive manner, and unlike conven‑
tional PPIs, functions in the absence of an acidic environment. 
Furthermore, vonoprazan accumulates in parietal cells and 
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provides more consistent acid suppression compared with other 
PPIs (16). Previous studies have demonstrated the efficacy of 
vonoprazan for the treatment of refractory GERD in patients 
without SSc (17,18); however, the use of vonoprazan in patients 
with SSc complicated by GERD has not been investigated, to 
the best of our knowledge. Thus, the aim of the present study 
was to evaluate the efficacy of vonoprazan for the treatment of 
GERD in patients with SSc.
Materials and methods
Patients. The Nagasaki University Hospital Ethics Committee 
approved the present study protocol (approval nos. 16062704 
and 17082135). All investigations were performed in accordance 
with the 1964 Declaration of Helsinki (19). The informa‑
tion was obtained only from anonymized electronic medical 
records. According to the guidelines of the Nagasaki University 
Hospital Ethical Committee's official disclosure system, if the 
subject of the study has minimal risk, the patient may choose 
to opt out of a study through our institution's homepage (mh.
nagasaki‑u.ac.jp/research/rinsho/patients/open.html). Informed 
consent was obtained from all patients in this study.
The present study was performed between July 1, 
2016 and May 31, 2017 at Nagasaki University Hospital. A 
total of 17 outpatients with GERD who received vonoprazan 
treatment at the Department of Dermatology, Immunology and 
Rheumatology were retrospectively recruited. The exclusion 
criteria included age (patients <20 and >90 years of age), and 
those who did not provide informed consent. Of the 17 enrolled 
patients with GERD, two patients who were eventually diag‑
nosed with morphea or mixed connective tissue disease, during 
the course of treatment, were excluded. Thus, 15 participants 
were recruited in the final cohort [1 male (6%) and 14 females 
(94%); median age, 64 years (range: 36‑78); limited cutaneous 
(lc)SSc, n=11 (73%); diffuse cutaneous (dc)SSc, n=4 (26%)]. 
GERD treatment scores with a frequency scale for symptoms 
of GERD (FSSG) (20), and on and off (previous) vonoprazan 
treatment was recorded. Characteristics of participating patients 
and the endoscopic findings of GERD were collected from 
electronic records. The mean observation period of endoscopy 
was 7.5 weeks (range, 0‑32 weeks) before vonoprazan treat‑
ment. History of the use of various anti‑acids were found, but 
only previous use the anti‑acids of vonoprazan was recorded. 
Conventional PPIs and H2RA included esomeprazole 
20 mg/day, lansoprazole 30 mg/day, rabeprazole 10 mg/day and 
famotidine 20 mg/day. Duration of treatment with previous PPIs 
was 20 to 436 weeks and with H2RA treatment it was 8 weeks.
In 2 patients out of 15, in addition to recording the above 
information, 24‑h pH monitoring and high‑resolution manom‑
etry (HRM) was performed, both before and after 12 weeks 
of vonoprazan therapy. Patients were observed for 4‑28 weeks 
after beginning vonoprazan. Patients who underwent the 24‑h 
pH monitoring and HRM provided informed consent before 
participating in the present study.
Diagnosis of SSc. Patients were categorized into dcSSc and 
lcSSc groups, according to the range of skin hardening and 
other factors, including the presence of auto‑antibodies 
and complications (21). Anti‑topoisomerase‑I antibody 
and anti‑RNA polymerase antibody positivity suggested 
dcSSc, and anticentromere antibody positivity confirmed 
lcSSc. Additionally, the period between diagnosis and occur‑
rence of SSc, the modified Rodnan total skin thickness score 
(MRSS), Raynaud's phenomenon, digital ulcer, pulmonary 
arterial hypertension (diagnosed by cardiac echocardiography) 
and interstitial lung disease (diagnosed by high‑resolution 
computed tomography) was recorded.
Treatment with vonoprazan. The dose of vonoprazan adminis‑
tered to patients (either 10 or 20 mg/day) was determined by the 
patient's attending physician. A total of 7 patients were treated 
with 20 mg vonoprazan from the beginning of the study and 
8 patients were started on 10 mg/day vonoprazan, of which, 
4 patients were increased to 20 mg/day after 4‑17 weeks, due 
to insufficient effects at 10 mg/day.
FSSG. The FSSG score developed by Kusano et al (20), has 
been reported to correctly identify GERD and reflect disease 
severity and treatment efficacy in Japanese GERD patients (22). 
Patients filled in the questionnaire before vonoprazan treat‑
ment (baseline) in all patients. A follow‑up questionnaire was 
filled in after at least 4 weeks of treatment (range, 4‑28 weeks 
follow‑up). The total FSSG score was 48 points, and scores >8 
indicated GERD.
Esophageal HRM and 24‑h pH monitoring. A pH electrode 
catheter (Catheter, SA100; Pocket Monitor, GMMS‑200pH; 
Star Medical) sensor was placed 5 cm above the esophagogas‑
tric junction under X‑ray guidance and maintained for 24 h. 
The data was analyzed using pH.dll software (Star Medical). 
The Demeester score (23), acid exposure time (AET; defined 
as the ratio of the total time the distal esophageal pH was 
<4 to the total monitoring time), number of reflux events 
lasting >5 min and the total number of acid reflux events 
were recorded. Esophageal motility was assessed using HRM 
(Catheter, PD1236K, Pocket Monitor: GMMS‑4000, Star 
Medical) according to the Chicago Classification system 
version 3.0 (24).
Statistical analysis. Data was analyzed with JMP software (ver. 
15.0.0; SAS institute). Patient's data are presented as the median 
(range). The FSSG scores before and after vonoprazan treatment 
were compared using a Wilcoxon's paired rank sum test. For 
comparison of the improvement rate between the starting dose 
of 10 and 20 mg of vonoprazan and for the comparison of diges‑
tive involvement with SSc patients and the improvement rate of 
vonoprazan treatment, the Wilcoxon's unpaired rank sum test 
was used. A Kruskal‑Wallis test followed by a post‑hoc Dunn's 
test was used for comparison between the improvement rate of 
vonoprazan and each SSc grade. P<0.05 was considered to indi‑
cate a statistically significant difference. The improvement in the 
FSSG scores was adjusted to account for differences in the dura‑
tion of disease according to the following equation: Improvement 
rate=(before vonoprazan treatment score‑post‑treatment 
score)/before vonoprazan treatment score x100.
Results
Patient background. A total of 15 outpatients with SSc 
complicated by GERD were treated with vonoprazan during 
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the study period. A total of 2 patients (13%) had pulmonary 
hypertension and 7 (46%) had pulmonary fibrosis. The median 
(range) MRSS was 7.7 (0‑26). Symptoms of Raynaud's phenom‑
enon occurred in 13 (86%) patients and 3 (20%) patients had 
a digital ulcer (Table I). Gastrointestinal symptoms included 
heartburn, epigastric pain, dysphagia, vomiting, constipation 
and weight loss in 14 (93%), 6 (40%), 6 (40%), 5 (33%), 4 (26%) 
and 1 (6%) patient, respectively. The mean duration of SSc 
was 10.2±5.3 years. In the patients, 8 started vonoprazan at 
10 mg/day, whereas 7 started at 20 mg/day. Of the 15 patients, 
14 patients (93%) had previously been treated with conventional 
PPIs and H2RA without relief (Fig. S1A). Only, 1 patient had 
discontinued the PPI despite recurring GERD symptoms, due 
to a fear of the side effects. The median period of conventional 
PPIs and H2RA treatment was 122 weeks (range, 8‑436 weeks).
Amongst all the 15 patients, previous medications included 
esomeprazole (n=9, 60%), lansoprazole (n=2, 13%), rabeprazole 
(n=2, 13%) and famotidine (n=1, 7%), with one patient (7%) not 
having received any prior treatment (Fig. S1A). Approximately 
75% of patients had previously received a prokinetic agent 
(mosapride citrate or metoclopramide) (Fig. S1B).
A total of 11 patients underwent endoscopy and the 
Los Angeles (LA) grading (25) of GERD before initiation of 
vonoprazan treatment. A majority of patients (n=8, 72%) had 
a normal or slightly inflamed esophageal mucosa (LA Grade 
N/M) regardless of symptom severity (Table II). A total of 
3 patients (27%) had slight to moderate esophagitis (LA grade 
A/B), and none had severe esophagitis (LA grade C).
FSSG score assessment before and after vonoprazan. The 
mean baseline total FSSG, acid reflux and dysmotility scores 
(standard deviation) were 25.2 (10.7), 14.1 (6.6) and 11.1 
(4.6), respectively, before vonoprazan treatment (Table III). 
The mean of all three scores significantly improved after 
4‑28 weeks of vonoprazan treatment in patients receiving either 
10 or 20 mg/day (mean scores, 9.6, 4.6 and 4.8, respectively; 
Table III). A significant improvement in the mean total and acid 
reflux FSSG score was observed: 60.8 ±21.2 and 67.3±24.8%, 
respectively (Table III). Somewhat unexpectedly, the mean 
dysmotility score also showed an improvement (55.4±26.0%). 
In the 7 patients who received vonoprazan 20 mg/day from 
the beginning, the mean FSSG total, acid reflux and dysmotility 
score improvement rates were 65.7, 73.5 and 60.4%, respec‑
tively. In contrast, in the 8 patients who started treatment 
at 10 mg/day, the median improvement rates were modest 
at 29.9, 39.1 and 25.8%, respectively, which was signifi‑
cantly less compared with those who began treatment with 
20 mg/day (Fig. 1).
Of the 8 patients who started at 10 mg, in 4 patients, this 
dose was ineffective and were thus increased to 20 mg vono‑
prazan, which was effective. The remaining 4 patients remained 
on 10 mg owing to a sufficient beneficial effect at that dose. 
Regarding whether symptoms of digestive tract involve‑
ment in SSc other than reflux esophagitis (dysphagia, epigastric 
pain, vomiting, weight loss and constipation) affected the 
effects of vonoprazan on GERD symptoms in patients with 
dysphagia, GERD symptoms showed less improvement, 
whereas the presence of other symptoms did not affect the 
Table Ⅰ. Characteristics of SSc patients with gastroesophageal 
reflux disease.
Characteristic Value, n=15
Age, median (range) 64 (36‑78)
Sex, n (%)
  Male 1 (6)
  Female 14 (93)
SSc duration, median years (range) 10 (0‑19)
SSc subtype
  dcSSc, n (%)   4 (26)
  lcSSc, n (%) 11 (73)
MRSS, median score (range) 5 (0‑26)
Autoantibody subtype
  Topoisomerase‑1, n (%)   3 (20)
  Centromere, n (%)   4 (26)
  RNA polymerase, (%)   2 (13)
  Other, unknown, n (%)   6 (40)
Pulmonary hypertension, n (%)   2 (13)
Interstitial lung disease, n (%)   7 (46)
Raynaud's syndrome, n (%) 13 (86)
Digital ulcer, n (%)   3 (20)
Symptoms, n (%)
  Heartburn 14 (93)
  Dysphagia   6 (40)
  Epigastric pain   6 (40)
  Vomiting   5 (33)
  Constipation   4 (26)
  Weight loss 1 (6)
Previous therapeutic drug, n (%)
  Histamine‑2 receptor antagonist 1 (7)
  Proton pump inhibitor 13 (86)
SSc, systemic sclerosis; dcSSc, diffuse cutaneous systemic scle‑
rosis; lcSSc, limited cutaneous systemic sclerosis; MRSS, Modified 
Rodnan skin score.
Table II. Gastroesophageal reflux disease grade according to 
the modified LA classification before vonoprazan treatment.
Modified LA grade before treatment n, (%)a
N/M 8 (72)
A/B 3 (27)
C/D 0 (0) 
aOf the 15 patients, 11 underwent an endoscopy before vonozapran 
treatment (0‑32 weeks before vonoprazan treatment). N, no changes 
at the EGJ; M, minimal change without mucosal break at the EGJ; 
A, <5 mm erosion at the EGJ; B, >5 mm erosion at the EGJ or in the 
lower esophagus and no connection to the next erosion; C, >2 lines 
of erosion at the EGJ with connection to another erosion, D, circum‑
ferential involvement or stricture at the EGJ. LA, Los Angeles; EGJ, 
esophagogastric junction.
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effect of vonoprazan (Fig. 2). Patients with dysphagia had a 
significantly lower rate of improvement.
Side effects (diarrhea, nausea, vomiting, skin rash and 
erythema multiforme) of vonoprazan were not reported in the 
follow‑up period.
Additionally, association analysis between the grade of 
SSc (26) and the improvement rate of vonoprazan (using a 
Kruskal‑Wallis test) was assessed. However, there were no 
statistically significant differences amongst these (Fig. 3).
Assessment of 24‑h pH monitoring and HRM in two patients. 
In two cases, 24‑h pH monitoring and HRM were recorded 
at baseline and after 12 weeks of vonoprazan treatment. 
The baseline to after treatment total FSSG scores decreased 
from 30 to 7 (Case 1) and 9 to 4 (Case 2), and endoscopic 
examination revealed evidence of mild erosions in both cases. 
After 20 mg/day vonoprazan treatment, both patients showed 
improved endoscopic findings (Fig. 4A). These two patients 
had severe reflux observed with 24‑h pH monitoring, indi‑
cating excessive AET (76 and 97%). Notably, supine position 
AET was increased (77 and 87%) and the baseline Demeester 
scores were also high (Fig. 4B). The AET and Demeester 
scores showed a trend towards mild improvement following 
treatment (Fig. 4B).
HRM revealed absent contractility and hypotensive LES 
(3.6 and 3.8 mmHg, respectively; Fig. 4C). No significant 
changes in esophageal pressure topography of HRM was 
observed between before and after treatment with vonoprazan, 
despite the improved FSSG motility disorder scores in each 
patient (12 to 6 and 5 to 3, respectively).
Discussion
To the best of our knowledge, the present study is the first to 
describe the effects of vonoprazan in a SSc patient popula‑
tion. The majority of SSc patients in the present study had 
experienced severe gastroesophageal symptoms that persisted 
regardless of treatment with conventional PPIs (Table I). 
Although all patients had symptoms of GERD, the endoscopic 
evidence of esophagitis tended to be modest even in those 
with severe symptoms, which is in contrast to a report by 
Thonhofer et al (27), who showed that 77% of asymptomatic 
SSc patients had esophageal erosions. This difference in find‑
ings may be due to the administration of PPI prior to initiation 
of vonoprazan treatment in the majority of the patients in the 
current study, and suggest that physicians should not judge 
the severity of esophageal manifestations based on mucosal 
erosion alone.
The primary scoring systems for GERD is the FSSG as well 
as the modified FSSG (28). FSSG primarily takes into consid‑
eration reflux symptoms, whereas the modified FSSG score is 
beneficial for the differentiation of functional dyspepsia and 
Table Ⅲ. FSSG scores in patients with systemic sclerosis‑related GERD before and after vonoprazan treatment.
FSSG score Before vonoprazan After vonoprazanc Mean improvement rated ± SD P‑valuee
Total score, mean (SD) 25.2 (10.7) 9.6 (7.0) 60.8%±21.2 0.0004b
Acid reflux score, mean (SD) 14.1 (6.6) 4.6 (5.1) 67.3%±24.8  <0.0001b
Dysmotility score, mean (SD) 11.1 (4.6) 4.8 (3.5) 55.4%±26.0  0.0022a 
aP<0.05, bP<0.001. cVonoprazan dose, 10 or 20 mg/day. dImprovement rate=(before vonoprazan score‑after vonoprazan treatment score)/before 
vonoprazan score x100 (%). The duration of observation was 4‑28 weeks after vonoprazan treatment. eA Wilcoxon paired test was used. GERD, 
gastroesophageal reflux disease; FSSG, frequency score for symptoms of GERD; SD, standard deviation.
Figure 1. Comparison of improvement rates between a starting dose of 10 or 20 mg vonoprazan in all 15 patients. The scatter diagram compares the improve‑
ment rates for the difference in initial vonoprazan dose; 10 mg (4‑17 weeks after vonoprazan) vs. 20 mg (6‑28 weeks after vonoprazan). The symptom 
improvement rates of 20 mg were significantly higher than those of 10 mg in all three categories. Thus, a top‑down therapy of 20 mg vonoprazan may be better 
than starting at 10 mg. *P<0.05.
BIOMEDICAL REPORTS  14:  25,  2021 5
Figure 2. A comparison of digestive involvement with SSc patients and the improvement rate of FSSG with vonoprazan treatment. The scatter diagram shows 
the effect of vonoprazan on GERD symptoms (the improvement rate of vonoprazan) under the presence or absence of general gastrointestinal symptoms in SSc. 
In the presence of dysphagia, the improvement rate was significantly lower. The duration of the observation period was 4‑28 weeks after vonoprazan treatment. 
*P<0.05. SSc, systemic sclerosis; GERD, gastroesophageal reflux disease; FSSG, frequency scale for symptoms of GERD.
Figure 3. Association analysis between SSc grade and the improvement rate of FSSG following treatment with vonoprazan. The scatter diagram shows a 
comparison of the severity of each organ disorder in SSc patients and improvement rate following treatment with vonoprazan. The period of observation was 
4‑28 weeks after vonoprazan treatment. There were no significant differences found in any of the comparisons. SSc, systemic sclerosis; FSSG, frequency scale 
for symptoms of gastroesophageal reflux disease.
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GERD (28). In the present study, FSSG was used as the patient 
was determined to have GERD and the aim of the study was to 
assess the improvement of the reflux symptoms.
In the present study, endoscopic mucosal lesions were mild 
despite the severity of GERD symptoms. Conventional PPIs 
had already been administrated in the majority of patients, 
which may have resulted in mild or no mucosal damage of the 
esophago‑gastric junction, despite the presence of GERD symp‑
toms (29). Although grade C/D patients were not included in the 
present study, vonoprazan has been reported to have better effects 
with improved erosion in severe patients compared to PPI (30).
The effect of conventional PPIs is influenced by three 
CYP2C19 genotype classes: Extensive metabolizer (EM), 
intermediate metabolizer (IM) and poor metabolizer (31). The 
majority of Japanese individuals are EMs and IMs; thus, a 
sufficient antacid effect cannot be obtained with conventional 
PPIs (32). Vonoprazan does not exhibit this CYP2C19 geno‑
type dependency as it is primarily metabolized by CYP3A4. 
Therefore, vonoprazan has been shown to exhibit a more 
constant and rapid acid suppressive effect than conventional 
PPIs in Japanese patients (16,32). As previous studies on vono‑
prazan were performed primarily in Japan, further research in 
patients of other nationalities is required.
A previous study showed that the 24‑h intra‑gastric 
pH>4 holding time ratio (HTR) of vonoprazan is extremely 
high (33); in healthy Japanese men receiving treatment with 
20 or 40 mg/day vonoprazan for 7 days, the intra‑gastric 
pH>4 HTRs were 83.4 and 100%, respectively. Notably, the 
night‑time intra‑gastric pH>4 HTR with 40 mg/day vono‑
prazan was 100% in Japanese patients (34). The present study 
showed that vonoprazan markedly reduced GERD symptoms 
as demonstrated by improved FSSG scores, particularly the 
acid reflux score. In fact, 24‑h pH monitoring revealed a trend 
toward decreased AET when lying down in 2 patients. In SSc 
patients, gravity serves a major role in the esophageal acid 
clearance time, and delayed acid clearance in the supine posi‑
tion may suggest initial esophageal involvement (35). Thus, it 
is hypothesized that vonoprazan, at least partially, improved 
GERD symptoms in the patients with SSc compared to PPIs, 
due to the more efficient suppression of acid at night.
In the present study, only 50% of SSc patients on 10 mg 
showed improvement. Generally, GERD treatment requires 
sufficient acid suppression, defined as an intra‑gastric pH >4 
HTR within 83‑91% (33). However, with 10 mg/day vonoprazan 
treatment, pH>4 HTR was shown to be reached in 63.3% patients. 
In contrast, with 20 mg/day vonoprazan treatment, pH>4 HTR 
Figure 4. Results of endoscopic findings, 24‑h pH monitoring and HRM. (A) Endoscopic changes before and after vonoprazan treatment using white light and 
narrow band imaging. (B) Comparison of individual 24‑h pH monitoring results at baseline and after vonoprazan treatment. n=2. (C) HRM imaging with pres‑
sure topography plots at baseline and after treatment. n=2. The images were selected at representative points from each examination. HRM, high‑resolution 
manometry; AET, acid exposure time.
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was reported to be reached in 83.4% of patients (33). Thus, in 
SSc patients with PPI‑resistant GERD, top‑down therapy, with 
a starting dose of 20 mg/day vonoprazan, may be more appro‑
priate than starting at 10 mg. Although the long‑term effects of 
vonoprazan in SSc patients remains unknown, the symptoms of 
the patients on vonoprazan whom are being followed up (13 out 
of 15 patients) have been well controlled for >2 years.
Side effects of vonoprazan include nausea, vomiting, 
constipation, abdominal pain, skin rashes and heartburn, 
which are similar to those of classic PPIs (16). Although the 
long‑term side effects of vonoprazan have not yet been fully 
elucidated, it has been reported to induce higher gastrin 
levels compared with PPIs, which has the potential to lead to 
enterochromaffin‑like cell hyperplasia as well as potentiating 
the development of carcinoid tumors (36), hyperparathy‑
roidism (32,33,37) hypomagnesemia and hypocalcemia (38). 
Considering these facts, careful monitoring of the develop‑
ment of endocrine cell tumors should be performed.
The present study found that the effects of vonoprazan 
were rather limited in the presence of dysphagia, which is a 
common symptom in patients with SSc (39). Although the 
reason for this tendency is unclear, it is hypothesized that 
vonoprazan may not sufficiently counteract the GERD symp‑
toms in patients with a significant decrease in esophageal 
movement. Conversely, no association was found between the 
grade of SSc and the improvement rate of vonoprazan.
There are several limitations to the present study. The first 
is the design, as it was a single‑arm, retrospective study with no 
comparison groups. The second limitation concerns the lack 
of patients with endoscopically severe esophagitis presented 
as LA grade C/D. Furthermore, there were variations in the 
observation period due to the retrospective nature of the study. 
A future large‑scale prospective comparative study should be 
performed to confirm the results.
In conclusion, SSc patients with GERD, including those 
refractory to conventional PPI therapy, experienced significant 
relief from symptoms when treated with 20 mg/day vonoprazan. 
The results demonstrate the efficacy of vonoprazan for the treat‑
ment of GERD in SSc patients with PPI‑resistant symptoms, 
which may lead to an improvement in the patients quality of life.
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